Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
The company is bringing precision therapies for gynaecological cancers
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Subscribe To Our Newsletter & Stay Updated